Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00019591 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
NCT00019591: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00019591 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00019591, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Vaccines may make the body build an immune response that will kill cancer cells. Combining vaccine therapy with interleukin-2 may kill more cancer cells. PURPOSE: Phase I/II trial to study the effectiveness of vaccine therapy with or without interleukin-2 in treating patients who have locally advanced or metastatic colorectal cancer.
Interventions
- BIOLOGICAL aldesleukin
- PROCEDURE adjuvant therapy
- BIOLOGICAL ras peptide cancer vaccine
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-03 |
| Est. Completion | 2005-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00019591
The ClinicalTrials.gov registry entry for NCT00019591 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which aldesleukin is the first listed.
NCT00019591 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00019591 about?
NCT00019591 is a clinical study titled "Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer". RATIONALE: Vaccines may make the body build an immune response that will kill cancer cells. Combining vaccine therapy with interleukin-2 may kill more cancer cells. PURPOSE: Phase I/II trial to study the effectiveness of vaccine therapy with or without interleukin-2 in treating patients who have lo...
What is the current status of trial NCT00019591?
This trial is currently completed. It is a Phase 1 study. The study started on 1999-03. Estimated completion is 2005-11.
What interventions are being tested in trial NCT00019591?
The interventions under investigation include: aldesleukin (BIOLOGICAL), adjuvant therapy (PROCEDURE), ras peptide cancer vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00019591?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.